Sino Biopharmaceutical Limited logo

Sino Biopharmaceutical Limited

1177.HK

HKSEHealthcareMedical - Pharmaceuticals

Latest quote

HK$5.59

−HK$0.015 · -0.27%

Aug 24, 3:55 PM HKT

1177.HK company overview

Regular session · HKT · Market data may be delayed.

Company profile

Company website

Sino Biopharmaceutical Limited, an investment holding company, operates as a research and development pharmaceutical conglomerate in the People’s Republic of China. It operates through three segments: Modernised Chinese Medicines and Chemical Medicines, Investment, and Others. The company offers oncology medicines, including anlotinib hydrochloride capsules under Focus V brand, penpulimab injection under Annike brand, efbemalenograstin alfa injection under Yilishu brand, benmelstobart injection under Andewei brand, unecritinib fumarate capsules under Anboni brand, envonalkib citrate capsule under Anluoqing brand, garsorasib tablets under Anfangning brand, bevacizumab injection under Anbeisi brand, rituximab injection under Delituo brand, trastuzumab for injection under Saituo brand, and pertuzumab injection, under Paletan brand; liver disease medications, such as magnesium isoglycyrrhizinate injection under Tianqing Ganmei brand and entecavir dispersible tablets under Runzhong brand; and respiratory system medicines comprising budesonide suspension for inhalation under Tianqing suchang brand, and colistimethate sodium for injection under Tianyun brand. It also provides surgery/analgesia medicines, including flurbiprofen cataplasms under the brand Zepolas, limaprost tablets under the brand Kailitong, and recombinant human coagulation factor VIII for injection under the brand Anhengji. In addition, the company develops liver disease drugs, such as Lanifibranor and TQA2225; respiratory system drugs comprising TDI01, TQC2731, TCR1672, TQC3721, and TQH2722; and surgery/analgesia drugs, including PL-5, an antimicrobial peptide, TRD205, an AT2R inhibitor, and TRD303, a ropivacaine sustained-release solution. Further, it is involved in the long-term investments; and healthcare and hospital business. The company was incorporated in 2000 and is headquartered in Wan Chai, Hong Kong.

Industry
Medical - Pharmaceuticals
Sector
Healthcare
Headquarters
HK
CEO
S Y Tse
Listed since
May 12, 2004
Employees
22,838

Market position

Volume
94.31M
1.03× average
Average volume
91.76M
Average daily volume
Market cap
99.4B HKD
Beta
0.62
Market reference 1

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
108.9B CNY
EV / EBITDA
15.01×
Earnings yield
2.34%
Free cash flow yield
7.57%

Profitability & efficiency

Return on equity
7.64%
Return on assets
3.08%
Return on invested capital
8.98%

Financial health

Current ratio
1.37×

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends90%60%30%-0%Gross margin, FY2021: 80.15%Gross margin, FY2022: 82.76%Gross margin, FY2023: 80.95%Gross margin, FY2024: 81.51%Gross margin, FY2025: 82.07%Operating margin, FY2021: 18.91%Operating margin, FY2022: 21.46%Operating margin, FY2023: 22.08%Operating margin, FY2024: 21.26%Operating margin, FY2025: 21.84%Net margin, FY2021: 54.38%Net margin, FY2022: 9.77%Net margin, FY2023: 8.90%Net margin, FY2024: 12.12%Net margin, FY2025: 7.36%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 80.15%. Gross margin FY2022 82.76%. Gross margin FY2023 80.95%. Gross margin FY2024 81.51%. Gross margin FY2025 82.07%. Operating margin FY2021 18.91%. Operating margin FY2022 21.46%. Operating margin FY2023 22.08%. Operating margin FY2024 21.26%. Operating margin FY2025 21.84%. Net margin FY2021 54.38%. Net margin FY2022 9.77%. Net margin FY2023 8.90%. Net margin FY2024 12.12%. Net margin FY2025 7.36%.

Income trends

Revenue

31.83B CNY+10.28%

Operating income

6.95B CNY+13.33%

Net income

2.34B CNY-33.04%
Income trends across reported periods34.78B CNY22.98B CNY11.18B CNY−618.32M CNYRevenue, FY2021: 26.86B CNYRevenue, FY2022: 26.03B CNYRevenue, FY2023: 26.2B CNYRevenue, FY2024: 28.87B CNYRevenue, FY2025: 31.83B CNYOperating income, FY2021: 5.08B CNYOperating income, FY2022: 5.59B CNYOperating income, FY2023: 5.79B CNYOperating income, FY2024: 6.14B CNYOperating income, FY2025: 6.95B CNYNet income, FY2021: 14.61B CNYNet income, FY2022: 2.54B CNYNet income, FY2023: 2.33B CNYNet income, FY2024: 3.5B CNYNet income, FY2025: 2.34B CNYFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 26.86B CNY. Revenue FY2022 26.03B CNY. Revenue FY2023 26.2B CNY. Revenue FY2024 28.87B CNY. Revenue FY2025 31.83B CNY. Operating income FY2021 5.08B CNY. Operating income FY2022 5.59B CNY. Operating income FY2023 5.79B CNY. Operating income FY2024 6.14B CNY. Operating income FY2025 6.95B CNY. Net income FY2021 14.61B CNY. Net income FY2022 2.54B CNY. Net income FY2023 2.33B CNY. Net income FY2024 3.5B CNY. Net income FY2025 2.34B CNY.
Metric (CNY)FY2025FY2024FY2023FY2022FY2021
Revenue31.83B CNY28.87B CNY26.2B CNY26.03B CNY26.86B CNY
Cost of goods sold5.71B CNY5.34B CNY4.99B CNY5.8B CNY5.33B CNY
Gross profit26.13B CNY23.53B CNY21.21B CNY21.54B CNY21.53B CNY
Research and development6.04B CNY5.23B CNY4.47B CNY4.33B CNY3.75B CNY
Selling, general, and administrative13.14B CNY12.16B CNY11.07B CNY12.56B CNY12.7B CNY
Operating expenses19.17B CNY17.39B CNY15.54B CNY15.95B CNY17.19B CNY
Interest income617.19M CNY499.56M CNY186.68M CNY195.91M CNY162.06M CNY
Interest expense271.11M CNY295.12M CNY495.24M CNY429.49M CNY308.62M CNY
Depreciation and amortization963.9M CNY939.85M CNY1.07B CNY1.05B CNY992.56M CNY
Operating income6.95B CNY6.14B CNY5.79B CNY5.59B CNY5.08B CNY
Net income2.34B CNY3.5B CNY2.33B CNY2.54B CNY14.61B CNY

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
55%
6 beats, 5 misses, 0 met estimates
Average EPS surprise
+8.01%
11 comparable reports
Latest EPS result
0.22
Estimate 0.14 · Beat by 58.56%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates0.260.180.090.01Q3 '23BeatQ1 '24MissQ3 '24BeatQ1 '25MissQ3 '25BeatQ1 '26MissQ3 '26BeatQ2 '27Estimate
Q3 2023, reported Aug 25, 2023: actual 0.086, estimate 0.076, surprise +13.71%, Beat. Q1 2024, reported Mar 28, 2024: actual 0.05, estimate 0.088, surprise -43.75%, Miss. Q3 2024, reported Aug 13, 2024: actual 0.082, estimate 0.075, surprise +9.44%, Beat. Q1 2025, reported Mar 20, 2025: actual 0.032, estimate 0.085, surprise -62.50%, Miss. Q3 2025, reported Aug 18, 2025: actual 0.205, estimate 0.131, surprise +56.69%, Beat. Q1 2026, reported Mar 26, 2026: actual 0.011, estimate 0.067, surprise -83.43%, Miss. Q3 2026, reported Aug 19, 2026: actual 0.22, estimate 0.139, surprise +58.56%, Beat. Q2 2027, reported Apr 1, 2027: actual —, estimate 0.117, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates23.34B19.26B15.19B11.12BQ3 '23MissQ1 '24MissQ3 '24BeatQ1 '25MissQ3 '25MissQ1 '26MissQ3 '26BeatQ2 '27Estimate
Q3 2023, reported Aug 25, 2023: actual 16.51B HKD, estimate 16.57B HKD, surprise -0.39%, Miss. Q1 2024, reported Mar 28, 2024: actual 12.02B HKD, estimate 16.42B HKD, surprise -26.83%, Miss. Q3 2024, reported Aug 13, 2024: actual 17.02B HKD, estimate 16.28B HKD, surprise +4.51%, Beat. Q1 2025, reported Mar 20, 2025: actual 13.83B HKD, estimate 15.07B HKD, surprise -8.27%, Miss. Q3 2025, reported Aug 18, 2025: actual 19.15B HKD, estimate 19.18B HKD, surprise -0.15%, Miss. Q1 2026, reported Mar 26, 2026: actual 15.97B HKD, estimate 16.04B HKD, surprise -0.45%, Miss. Q3 2026, reported Aug 19, 2026: actual 22.44B HKD, estimate 22.29B HKD, surprise +0.68%, Beat. Q2 2027, reported Apr 1, 2027: actual —, estimate 19.37B HKD, surprise —, Comparison unavailable.

Corporate actions

Corporate action history

Dividend

Ex-dividend Jun 24, 2026

HK$0.07

Semi-Annual

Record Sep 3, 2026 · Payment Sep 24, 2026

Dividend

Ex-dividend Aug 29, 2025

HK$0.05

Semi-Annual

Record Sep 1, 2025 · Payment Sep 23, 2025

Dividend

Ex-dividend Jun 16, 2025

HK$0.04

Semi-Annual

Record Jun 17, 2025 · Payment Jul 10, 2025

Dividend

Ex-dividend Sep 10, 2024

HK$0.03

Semi-Annual

Record Sep 11, 2024 · Payment Oct 4, 2024

Dividend

Ex-dividend Jun 11, 2024

HK$0.03

Semi-Annual

Record Jun 12, 2024 · Payment Jul 5, 2024

Dividend

Ex-dividend Oct 4, 2023

HK$0.02

Semi-Annual

Record Oct 5, 2023 · Payment Oct 27, 2023

1177.HK peers

ETFs holding 1177.HK

Funds reporting this stock among their holdings, ordered by reported position size.

Continue in GoAI

Research 1177.HK

research.disclaimer